Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company employs 1,036 full-time employees The company went IPO on 2002-07-15. The firm operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The firm's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The firm mainly operates its business in mainland China, Hong Kong and Taiwan.
00950.HK stock price ended at $1.47 on 星期五, after rising 0.68%
On the latest trading day Feb 13, 2026, the stock price of 00950.HK rose by 0.68%, climbing from $1.46 to $1.47. During the session, the stock saw a volatility of 3.47%, with prices oscillating between a daily low of $1.44 and a high of $1.49. Notably, trading volume dropped by 33.8K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 726.0K shares were traded, equating to a market value of approximately $865.5M.